T he induction of inflammation is one of the primary hindrances to the success of adenoviral ( Ad ) -mediated gene therapy. Acute anti -Ad responses occur within hours of vector introduction as a result of activation of the innate immune system (i.e., neutrophils, macrophages ) . 3 ± 7 This leads to elevations of cytokines and chemokines resulting in recruitment of additional acute inflammatory cells. In addition to their toxic clinical effects, cytokine elevations, and other nonspecific acute inflammatory responses to viral vector instillation, also appear to impair gene transfer effectiveness in animal models. 5,8 ± 11 An obvious hypothesis generated by these findings is that pharmacologic blunting of Ad -induced inflammation would decrease toxicity and augment and prolong transgene expression. This hypothesis has been studied in a wide variety of animal models using compounds ranging from standard immunosuppressive agents such as corticosteroids, 5, 13, 14 cyclosporin, 15 FK506, 16, 17 and cyclophosphamide, 18 to chemotherapeutic and biological agents such as etoposide 16,19 ± 21 and anti -CD40 antibodies 22, 23 or CTLA4Ig. 24 The purpose of this trial was to evaluate this hypothesis, in a preliminary fashion, utilizing data obtained from a recently completed phase I, dose -escalation trial of Ad.HSVtk gene therapy in combination with systemic ganciclovir ( GCV ) in patients with advanced malignant pleural mesothelioma. 1 This trial demonstrated that high doses of replication incompetent Ad vectors administered into the pleural space were safe, although signs of systemic toxicity (i.e., fever, mild hypotension, and hypoxemia ) were observed. Doserelated gene transfer was demonstrated by multiple techni-ques, but appeared limited to the superficial tumor cell layers immediately below the mesothelial surface. In addition, immunological testing performed on all patients enrolled in the clinical trial demonstrated significant increases in serum and pleural fluid total and neutralizing anti -Ad antibodies, as well as increases in peripheral blood mononuclear cell ( PBMC ) proliferative responses to Ad. 2 Based on the data from animal models (see above ), we therefore reasoned those immune responses might be contributing to clinical toxicity and inhibiting the success of gene transfer. We thus hypothesized that administration of a powerful, but widely used and well -tolerated, antiinflammatory and immunosuppressive agent ( methylprednisolone ) immediately before and after vector delivery would decrease inflammatory responses leading to higher levels of gene transfer, lower acute clinical toxicity, and blunt anti -Ad humoral and cellular immune responses. Support for this latter idea was provided by experiments in our laboratory demonstrating that Ad -induced proliferative responses in PBMCs obtained from three mesothelioma patients could be inhibited with dexamethasone treatment in in vitro assays with IC 50 s ranging between 30 and 60 nM dexamethasone ( Molnar-Kimber, unpublished data ).
This hypothesis was tested in a small pilot study involving five mesothelioma patients in whom intrapleural delivery of Ad.RSVtk was combined with a short course of systemic corticosteroids at the time of vector instillation. These patients all received a high dose of vector (1.5Â10
13 viral particles ) in conjunction with a 3-day course of intravenous ( i.v. ) methylprednisolone beginning 10 hours before vector instillation. Toxicity, gene transfer, and immune responses were compared to five, consecutive, previously treated patients who received the same dose of vector, but without administration of systemic corticosteroids.
In this paper, we demonstrate that in the small number of patients studied, corticosteroid administration appeared to blunt acute inflammatory responses without effectively blocking anti -Ad humoral or cellular immunity.
MATERIALS AND METHODS

Gene transfer vector
The Ad vector (H5.010RSVtk ) used in this study is an E1 / E3 replication-incompetent Ad5 -based vector that was produced in the Human Applications Laboratory of the Institute for Human Gene Therapy at the University of Pennsylvania Medical Center (Philadelphia, PA ) under Good Manufacturing Practices ( GMP ) conditions. The detailed production of this vector has been described in detail elsewhere. 1, 25 Viral shedding: antibody fluorescent unit assays
To detect viral shedding, antibody fluorescent unit assays 26 were performed on stool, urine, and nasopharyngeal swabs obtained from study patients on days 1, 3, 5, 7, 14, and 19.
Routine histology and immunohistochemical ( IHC ) studies
Biopsies were subdivided into two portions. One was snapfrozen for immunohistochemistry, and the other portion was fixed in neutral buffered formalin for routine histology. Frozen sections of postvector delivery biopsies were stained using standard techniques. HSVtk protein was visualized using a 1:1 mixture of hybridoma supernatants from monoclonal antibodies 9G10 and 4C8 obtained from Dr. William Summers at Yale University. 1, 27 Ad type 5 neutralizing antibody ( NAb ) levels Blood obtained on the various days was clotted at room temperature and sera obtained. Samples were aliquoted and were stored at À 708C till use. The NAb titers were determined as previously described.
2,25
Total anti -Ad antibodies Total anti -Ad antibodies were measured using an ELISA described in detail previously. 2 
Immunoblots
For determination of anti -tk antibodies, lysates were made from REN or A549 cells and these cell lines infected with H5.010RSVtk or wild -type Ad (MOI= 10) . The lysates were homogenized, protein concentrations were measured and 100 g of protein was separated by 10% PAGE and transferred for 1.5 hours, as previously described. 2, 28 The primary antibody was either patient's sera (1:1000 or 1:2000 ) or rabbit anti -tk ( 1:2000 ) . 2, 28 The secondary antibodies, which were conjugated to alkaline phosphatase, were antihuman Ig (1:7500; Promega, Madison, WI ) and antiRabbit ( 1:7500; Promega, Madison, WI ).
Ad -specific proliferation
Ad -specific proliferation was measured as previously described in detail. 2 PBMCs were plated in a round -bottom 96 -well plate and stimulated with ultraviolet -inactivated Ad5 particles. After incubation for 6 days in a humidified 5% C0 2 in air atmosphere, the cells were pulsed with [ 3 H ]thymidine for 16± 18 hours and harvested and counted. Positive control cells were stimulated with phytohemagglutinin at 3 and 1 g/mL, pulsed on day 3 and harvested on day 4. Proliferation by tetanus toxoid (50 ng /mL ) was measured on day 7. Mean of the replicates + SEM ( SEM <15% ), and the stimulation index (cells + Ad5 /cells in media ) were calculated. Statistics were performed using a Student's t test ( unpaired) .
Gene transfer score
An overall assessment of gene transfer was assigned to each patient using a semiquantitative scoring system. 1 Although not truly quantitative in nature, the goal of this scoring system was to assign lower scores to HSVtk DNA detected 
Protocol
Patients were deemed eligible for this study if they had a histologically proven diagnosis of malignant pleural mesothelioma, were not candidates for resection, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and had a residual pleural space. Exclusion criteria included prior surgical resection, pleurodesis, chemotherapy or radiotherapy, or the presence of significant cardiac, hepatic, or renal disease. All patients signed a detailed informed consent form. The study and consent form were approved by (1 ) On day 1 of the study, patients were admitted to the General Clinical Research Center ( GCRC ) of the University of Pennsylvania Medical Center and underwent placement of a thoracostomy tube at the bedside under local anesthesia. Intravenous corticosteroid administration (methylprednisolone sodium succinate, Solu -Medrol1, Pharmacia-Upjohn, Peapack, NJ ) began on the night of admission and continued every 6 hours for a total of 12 doses. The original scheduled dose of methylprednisone was 125 mg every 6 hours, but this was decreased to 60 mg every 6 hours during the treatment of the second patient because of neurological side effects.
On day 2, approximately 10 hours after the initial corticosteroid dose, 1.5Â10 13 particles of the H5.010RSVtk viral vector, diluted in 100 mL of normal saline, were instilled into the pleural cavity via the thoracostomy tube. Three days later ( on day 5) , a videothoracoscopy was performed for tumor specimen acquisition. The following morning ( day 6) , i.v. GCV was initiated at 5 mg /kg given over 1 hour twice daily for 14 days. Nasal, urethral, and rectal swabs were obtained on a scheduled basis to evaluate for shedding of the recombinant viral vector. Blood samples were drawn for analysis of the anti -Ad and antitransgene immune responses. At the completion of the 14-day GCV course, patients were discharged from the GCRC for outpatient follow -up that included biochemical and hematological testing and a chestcomputed tomography scan performed on day 30.
Statistical methods
Comparisons of steroid and control patient data were made using unpaired Student's t test and Fisher's exact test ( Statview1, for Windows, Version 5.0, SAS Institute, Cary, NC ) Survival time was defined from study entry to death or date of last follow -up.
RESULTS
Patient enrollment
Five consecutive patients with malignant pleural mesothelioma ( patients 19 ±23) who met the aforementioned inclusion and exclusion criteria were enrolled in the pilot study (Table 1 ). All five patients were male with a mean age of 74 years. Four patients had epithelial mesothelioma; one had biphasic histology. Four of the patients had early stage disease (stage IA /IB ) ; one patient had more advanced mesothelioma ( stage IV ). All patients were able to undergo uncomplicated thoracostomy tube insertion under local anesthesia at the bedside to provide access for intrapleural vector instillation. All five patients received the same dose of H5.010RSVtk vector (1.5Â10 13 particles ) and GCV, as did five consecutive previously treated patients who did not receive corticosteroids ( Table 1 ) . These prior patients treated with vector alone (patients 14± 18 ) differed only slightly in their gender, age, tumor stage, and thoracic access procedure required for vector delivery ( Table 1 ) .
The first patient enrolled in the corticosteroid study, patient 19, received the full 12 doses of 125 mg of methylprednisolone. Patient 20 received five doses of 125 mg of methylprednisolone, but the sixth dose was held because of transitory mental status changes. After resolution, patient 20's corticosteroid dose was decreased to 60 mg for the next six doses. Patients 21 ± 23 received 60 mg of methylprednisolone every 6 hours for the full 12 doses. 
Toxicities
In the initial phase I trial, toxicities fell into four major categories: ( 1) liver enzyme elevation, (2 ) anemia, (3 ) fever after vector instillation, and ( 4) bullous exanthem surrounding the thoracic access site. A similar constellation of side effects was seen in this pilot study. The liver enzyme abnormalities, predominantly transaminase elevation, were all grade 2 or less, and all returned to normal within 1 month of completion of the protocol. There were no accompanying clinical symptoms of hepatic dysfunction associated with these liver enzyme abnormalities. There were no significant differences between the mean peak transaminase levels in the steroid -and non± steroid -treated patients at the same vector dose [AST, P=.92; ALT, P= .42 ] ( Table 2 ) . A transitory mild ±moderate anemia was seen in all five corticosteroidtreated patients (three grade 1, two grade 2 ) ( Table 2) . No patients in the study required blood transfusion. This anemia was felt to be multifactorial: secondary to phlebotomy, myelosuppressive effects of GCV, and anemia of chronic disease. There was no evidence of thrombocytopenia or disseminated intravascular coagulation. An erythematous vesiculo -bullous rash originating around the chest tube site was seen in two of the five patients receiving methylprednisolone, similar to the exanthem seen in all five of the non ± steroid -treated patients ( Table 2 ) . These skin eruptions were self -limited and did not require any medical intervention. Viral shedding was not detected in the blood, sputum, or urine of any patient. Consistent with the known anti -inflammatory characteristics of corticosteroids, the febrile response to intrapleural administration of recombinant Ad vector was abrogated in all five patients who received systemic methylprednisolone ( Table 2 ). The mean peak temperature postvector delivery among all five corticosteroid -treated patients was significantly lower (P=.003, 98.8 0.58F) than that seen in the untreated group ( 100.8 1.08F) . This correlated with a decreased incidence of other acute systemic inflammatory responses post virus instillation such as hypotension, hypoxemia, chills, and rigors. None of the patients receiving systemic corticosteroids developed hypoxemia within 24 ± 48 hours after vector instillation, compared with three of five patients treated at the same vector dose who did not receive steroids (Table 2 ) ( P= .08; Fisher's exact test ) .
Miscellaneous toxicities included one patient (patient 23) who developed a transient atrial tachyarrhythmia associated with mild hypotension that resolved spontaneously. The same patient also developed a grade 1 thrombocytopenia during the course of GCV treatment with no documented hemorrhagic complications. One patient (patient 20 ) in the corticosteroid group who had stage IV mesothelioma at the time of enrollment, died in the intensive care unit 2 weeks after completion of the protocol from rapid progression of his mesothelioma with malignant involvement of the contralateral hemithorax. There was no evidence of infectious complications relating to immune suppression induced by corticosteroid administration.
One obvious difference in toxicities between the two groups was that three patients in the steroid -treated group developed mental -status changes during the course of i.v. methylprednisolone. Two had grade 1 mental -status changes, primarily manifested by euphoria. A third patient ( patient 20 ), however, developed auditory and visual hallucinations, which resolved with a decrease in the methylprednisolone dose from 125 mg i.v. every 6 hours to 60 mg i.v. every 6 hours. All patients' mental status examinations returned to baseline by the completion of the protocol.
Gene transfer and efficacy
Intratumoral gene transfer was assessed in a semiquantitative fashion via IHC staining of parietal pleural biopsy specimens. All five patients in the steroid group had some evidence of HSVtk gene transfer to pleural tumor on IHC with a mean gene transfer score of 5.0 1.0 (see Materials and Methods for details of scoring system ). This score was not significantly higher (P= .374 ) than the mean gene transfer score in the nonsteroid group (4.2 1.3) ( Table 2 ) . Immunoblot analysis of patient serum revealed detectable levels of anti -HSVtk antibodies in three of four patients tested in the corticosteroid group compared with only one of five in the group of patients treated at the same vector dose level without steroids (P=.16, Fisher's exact test ) ( Table  3 ). These results demonstrate successful HSVtk gene transfer in the presence and absence of glucocorticoid administration, with no significant differences detected given the small numbers of patients enrolled. Evaluation of patient survival demonstrated no significant differences between the steroid -and non ±steroid -treated groups (Table 2) .
Cellular immune responses
We compared the cellular immune responses in our patients receiving concomitant Ad.tk /GCV and systemic corticosteroids to those patients treated with vector and GCV alone ( Table 3 ) . Small numbers of patients and large amounts of variability made determination of differences difficult; however, patients in the nonsteroid group appeared to have higher overall baseline stimulation indices ( mean 6.8) compared to the steroid -treated patients (mean 2.6) , but this difference was not statistically significant ( P=.13 ). The non ± steroid -treated group actually had lower increases in stimulation indices on day 19 after vector instillation compared with the steroid -treated patients ( mean 7.6 vs. 25.6 ) ; however, these decreased stimulation indices did not reach statistical significance ( P=.13 ). These data show that corticosteroid treatment did not prevent the ability of patients to develop cellular immune responses to Ad.
Humoral immune responses
All patients in both the corticosteroid -and non ± steroidtreated groups also developed humoral responses to the recombinant Ad (Table 3 ) . Baseline levels of total and neutralizing anti -Ad antibodies were similar in both steroidand non± steroid -treated patients. The mean baseline total anti -Ad Ab level in the nonsteroid patients (70.6 g/mL) was greater than that of the steroid -treated patients ( 58.5 STERMAN, MOLNAR -KIMBER, IYENGAR, ET AL: STEROIDS AND GENE THERAPY FOR MESOTHELIOMA g/ mL ) , but the difference was not statistically significant ( P= .8) . Increases in total and NAbs to Ad5 were detected in all patients within 15 days of the intrapleural instillation of viral vector ( Fig 1, Table 3 ). Unfortunately, these humoral responses were also heterogeneous within both groups making determination of differences difficult. Given the small number of patients and the high degree of variability, it is reasonable to state that corticosteroids did not prevent the ability of at least some of the patients from mounting strong anti -Ad humoral responses. For example, meso patients 22 and 23 in the corticosteroid group showed 250-to 300 -fold increases in their neutralizing Ad antibody titers ( Table 1 , Fig 1) . Two patients in the steroid group (patients 19 and 22 ) were also able to increase their total anti -Ad antibody titers by 20 -to 40-fold.
DISCUSSION
One major impediment to the successful use of Ad vectors for human gene therapy is the host antivector immune response that may impair gene transfer, destroy transduced cells, and block successful readministration. Another potential problem with Ad delivery is the generation of acute cytokine -mediated inflammatory responses that may induce dose-limiting, and even life -threatening, toxicities. Immune responses observed in various animal models include: (1 ) an immediate, doserelated inflammatory response mediated predominantly by neutrophils, macrophages and natural killer cells; 3,4,7,29 (2) cell -mediated lysis of transduced cells, limitation of transgene persistence, 30, 31 and delayed -type hypersensitivity responses to high vector doses; 15 and (3 ) production of NAbs that may inhibit effective vector readministration in animals. 32, 33 All of these responses have also been observed in human clinical trials to varying degrees. 2,34 ± 39 This pilot study provided a unique opportunity to preliminarily evaluate the effects of immunosuppression on Ad vector-mediated inflammation and immune responses in patients receiving intrapleural Ad.HSVtk. We chose to treat patients with a short course of high -dose corticosteroids based on efficacy in animal models, 40 the broad antiinflammatory and immunosuppressive effects of steroids, 41 the lack of serious short -term side effects, and the accepted clinical use of these drugs. We also felt this approach would be safe based on data from other human Ad gene therapy trials where patients had been receiving steroids chronically for advanced glioblastoma multiform as a means to decrease intracerebral edema. 42 Although not conducted in a blinded or randomized fashion, we prospectively compared the findings in a cohort of patients receiving corticosteroids with a group previously treated in exactly the same manner, but who did not receive corticosteroids.
Our results suggest that: ( 1) corticosteroid therapy in conjunction with intrapleural Ad.HSVtk vector may be safe, except for reversible mental -status changes at high -dose levels. We observed no evidence of increased virus shedding, other organ toxicity, or disseminated viral infection; ( 2) there were decreased immediate systemic inflammatory effects such as fever and hypoxemia; (3 ) there was detectable intratumoral HSVtk gene transfer and anti-HSVtk serum antibody generation postvector delivery in the steroid -treated group; and ( 4) unlike findings in some animal models, there were no significant decreases seen in the levels of anti -Ad antibodies or anti -Ad lymphocyte responses in the steroid -treated group. Some patients receiving steroids were able to show large increases in both anti -Ad antibodies and anti -Ad lymphocyte responses even after receiving high doses of corticosteroids.
Acute inflammatory responses have been observed in many animal models after a high -dose administration of Ad vectors via i.v. or intrapulmonary routes, 6, 43 and vigorous cytokine release is likely the cause of acute toxic reactions seen in some human trials. 34, 35 An acute inflammatory response is thought to have played a role in the recent death of a patient after intrahepatic Ad instillation. 44 In our initial phase I trial, at the highest intrapleural dose levels of the first generation -Ad.tk vector (5Â10 13 particles ), two of three patients exhibited transient hypotension and hypoxemia along with fevers to 102 ±1038F. 1 These side effects were short -lived, and the patients were able to complete the protocol without difficulty, but the concern remained that if the vector dose was further increased, this acute toxicity would prove to be significant and perhaps dose -limiting. Our study suggests that administration of systemic corticosteroids delivered at the time of vector instillation may mitigate some of these early responses. In addition, steroid administration may allow for vector administration at higher titers directly into organs that would otherwise be highly susceptible to Ad -induced inflammation, such as the liver, brain, and lung. Although we did not measure circulating levels of cytokines such as tumor necrosis factor and interleukin -6 in enough patients and at enough time points for meaningful statistical analysis, it is interesting that the mean serum levels of interleukin -6 and tumor necrosis factor-alpha were increased up to 72 hours postvector instillation in two non ± steroid -treated patients compared to two receiving systemic corticosteroids (data not shown) .
In contrast to the blunting of acute inflammation, our data suggest that corticosteroids alone may not be adequate to inhibit the humoral and cellular immunologic responses to the vector in humans. Patients receiving steroids still generated multifold increases in their serum anti -Ad NAb levels ( Table  3 , Fig 1 ) . High titers of such antibodies could potentially limit efficacy of repeat administrations of vector, although, in fact, little data to support this effect has been seen in humans to date. 2 Anti -Ad cellular immune responses were also induced to a similar degree in both patient groups ( Table 3) .
The reason for this lack of immunosuppression is not known. One explanation could be that in most humans receiving gene therapy with Ad vectors, the immune responses to Ad are secondary or memory type responses.
These memory responses are likely to be more difficult to blunt with steroids than would be primary responses. However, it is possible that, in a larger trial, the immunomodulatory effect of corticosteroids will become evident. Alternatively, it may be necessary to use other compounds such as cyclosporin, cyclophosphamide, or etoposide in human clinical trials that may have better efficacy in inhibiting chronic immune responses. Obviously, these agents are more toxic and carry greater risks of side effects than steroids. Utilization of promising, but unproven, biotherapeutics such as anti -CD40 antibodies 23 or CTLA4Ig 24 will be difficult to implement in the near future.
The inhibition of humoral, cellular, and cytokinemediated immune responses have obvious advantages in diseases where long -term gene transfer is the goal ( i.e., cystic fibrosis ). However, vector-initiated immune activation may be therapeutically useful in the context of cancer gene therapy for``cross -priming,'' that is, the induction of immune responses to the tumor in conjunction with the vector. 20,45 ± 47 The most useful type of antitumor immune responses in this regard would be generation of long -lived cytotoxic T cells. Thus, a balance between inhibition of the acute inflammatory responses (which limit the amount of vector that can be delivered ) and blockade of potential antitumor T-and B -cell responses needs to be achieved. With this goal in mind, long -term administration of agents with known ability to inhibit the generation of acquired immune responses ( i.e., cyclosporin, cyclophosphamide, or even anti -CD40 antibodies ) may not be ideal for cancer gene therapy. Our data suggest that a short course of high -dose corticosteroids, however, might be able to blunt the acute inflammatory responses seen with vector administration ( perhaps prolonging transgene expression ) whereas not significantly impacting on the generation of T-and B -cell responses (as measured by anti -Ad antibody responses and lymphocyte proliferation ). Although our numbers are small, preservation of immune response is supported by the observation that three of the five patients treated with steroids generated antibodies against the transgene, HSVtk. The effects of a short course of steroids on antitumor immune responses are unknown in humans, although we have some animal data to suggest that this approach might be helpful. 13 A major, recognized limitation of this study was the small number of patients enrolled in each group. The fact that each cohort had only five patients, coupled with the natural variability inherent in the human population, clearly restricts the statistical power of any positive or negative conclusions drawn. However, keeping these important limitations in mind, this study provides, to our knowledge, the first and only``controlled'' data regarding the effects of immunosuppression in human patients undergoing Ad gene therapy and should therefore be useful as a springboard to further studies.
In summary, administration of a short course of high -dose corticosteroids to patients receiving intrapleural gene therapy appeared to blunt acute inflammatory responses without effectively blocking anti -Ad humoral or cellular immunity. Addition of corticosteroids at the time of vector instillation may thus provide a useful method of blunting acute, vectorinduced toxicity. Randomized controlled studies in larger patient groups will be needed to test this hypothesis.
